Rachel Miller
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rachel Miller sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Rachel Miller: 6 sponsored US clinical trials, 2 recruiting.
Rachel Miller sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Endometrial Cancer, with 1 trials.
Upper-quartile sponsor footprint
Rachel Miller sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
NCT06677112
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
NCT03089554
PITCH - Impacting Hereditary Cancer Testing
NCT07090109
Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients
NCT03324945
Biobehavioral Intervention in Gynecologic Oncology Patients
NCT02454036
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
NCT01519869
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Rachel Miller pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Endometrial Cancer (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rachel Miller: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Rachel Miller sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Rachel Miller page
6 registered trials is a research-attention snapshot, not an endorsement of Rachel Miller or any single study.
- 2 of Rachel Miller's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Endometrial Cancer is the condition Rachel Miller studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Endometrial Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rachel Miller pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.